Next Article in Journal
Topical Application of a Collagen Mimetic Peptide Restores Peripapillary Scleral Stiffness Reduced by Ocular Stress
Previous Article in Journal
Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

An Alternative Mechanism of Glutamate Dehydrogenase Inhibition by EGCG: Promotion of Protein Degradation

College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, IDD and CB, Zhejiang University of Technology, Hangzhou 310014, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceuticals 2025, 18(6), 877; https://doi.org/10.3390/ph18060877
Submission received: 23 April 2025 / Revised: 3 June 2025 / Accepted: 6 June 2025 / Published: 12 June 2025
(This article belongs to the Section Pharmacology)

Abstract

Backgroud: Glutamate dehydrogenase (GDH) is involved in the metabolism of glutamate and ammonia. It is regulated by multiple ligand variants, and hyper-active GDH mutants have been reported for hyperinsulinism hyperammonemia syndrome (HHS). Methods: Here, we constructed the wild-type human GDH and three human GDH454 mutants and investigated their degradation activity and performance under different GDH inhibitors. Results: Protein activity test and SDS-PAGE analysis of the purified proteins showed that the GDH454 mutant from HHS has weaker GDH enzymatic activity but greater resistance to trypsin hydrolysis than the wild type. Interestingly, using the biomolecular interactions technique, it showed that the GDH454 mutant has 109 times weaker affinity for trypsin and 10-fold weaker for epigallocatechin gallate (EGCG) than the wild-type GDH. Subsequently, native-PAGE gel analysis demonstrated that EGCG could break down the GDH hexamer into monomers and form a complex with trypsin to enhance the degradation of both types of GDH. Conclusions: EGCG showed good affinity to both the wild-type and the mutant GDH proteins, promoting protein degradation; this provides a new strategy for the treatment of HHS and other hyper-active GDH-related diseases.
Keywords: EGCG; glutamate dehydrogenase; gene mutant; protein degradation; hyperinsulinism hyperammonemia syndrome EGCG; glutamate dehydrogenase; gene mutant; protein degradation; hyperinsulinism hyperammonemia syndrome

Share and Cite

MDPI and ACS Style

Zeng, Z.; Lin, C.; Pan, C.; Chen, Z.; Ruan, B.H. An Alternative Mechanism of Glutamate Dehydrogenase Inhibition by EGCG: Promotion of Protein Degradation. Pharmaceuticals 2025, 18, 877. https://doi.org/10.3390/ph18060877

AMA Style

Zeng Z, Lin C, Pan C, Chen Z, Ruan BH. An Alternative Mechanism of Glutamate Dehydrogenase Inhibition by EGCG: Promotion of Protein Degradation. Pharmaceuticals. 2025; 18(6):877. https://doi.org/10.3390/ph18060877

Chicago/Turabian Style

Zeng, Ziying, Chenshui Lin, Chuqiao Pan, Zhao Chen, and Benfang Helen Ruan. 2025. "An Alternative Mechanism of Glutamate Dehydrogenase Inhibition by EGCG: Promotion of Protein Degradation" Pharmaceuticals 18, no. 6: 877. https://doi.org/10.3390/ph18060877

APA Style

Zeng, Z., Lin, C., Pan, C., Chen, Z., & Ruan, B. H. (2025). An Alternative Mechanism of Glutamate Dehydrogenase Inhibition by EGCG: Promotion of Protein Degradation. Pharmaceuticals, 18(6), 877. https://doi.org/10.3390/ph18060877

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop